Preliminary assessment of magnetic resonance spectroscopic imaging in predicting treatment outcome in patients with prostate cancer at high risk for relapse

Darko Pucar, Jason A. Koutcher, Ankoor Shah, John P. Dyke, Lawrence Schwartz, Howard Thaler, John Kurhanewicz, Peter T. Scardino, W. Kevin Kelly, Hedvig Hricak, Kristen L. Zakian

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The purpose of the study was to determine whether 3D proton magnetic resonance spectroscopic imaging (MRSI) can predict treatment outcome in high risk patients with prostate cancer, Endorectal magnetic resonance imaging (MRI) and 1H-MRSI were performed in 16 patients with prostate cancer who were considered high risk because of clinical stage T3-4, Gleason score ≥ 8, and/or prostate-specific antigen (PSA) level > 20 ng/mL. Patients were treated with chemotherapy/hormone therapy, underwent radical prostatectomy (RP) or radiation therapy, and were followed for PSA relapse (follow-up, 19-43 months). The ratio of choline plus creatine to citrate was used to localize peripheral zone cancer. An MRSI risk score on a scale of 0-3 was derived from the volume and degree of metabolic abnormality. Magnetic resonance spectroscopic imaging risk score, MRI tumor/node (TN) stage, clinical stage, Gleason score, and PSA were used as predictors of pathologic stage in patients treated with RP (n = 10) and PSA relapse in all patients. Magnetic resonance imaging TN stage (P < 0.01) and MRSI risk score (P < 0.05) correlated with pathologic stage, but clinical stage did not (P = 0.35). Magnetic resonance imaging TN stage was the only significant predictor of PSA relapse in the univariate analysis (P < 0.05). Although the MRSI risk score did not reach significance (P = 0.13), 6 patients with a score < 0.9 were relapse-free, whereas 7 of 10 patients with a score > 0.9 relapsed. Magnetic resonance imaging and MRSI risk assessments agreed in 15 of 16 patients. These preliminary results suggest that tumor metabolic assessment may indicate treatment outcome in high-risk patients with prostate cancer. Although MRSI did not provide added prognostic value to MRI in this small number of patients, MRSI might increase the confidence of the clinician in assessing risk on MRI by contributing supporting metabolic data.

Original languageEnglish (US)
Pages (from-to)174-181
Number of pages8
JournalClinical Prostate Cancer
Volume3
Issue number3
DOIs
StatePublished - Jan 1 2004

Fingerprint

Prostatic Neoplasms
Magnetic Resonance Imaging
Recurrence
Prostate-Specific Antigen
Neoplasm Grading
Prostatectomy
Neoplasms
Creatine
Choline
Citric Acid
Protons
Radiotherapy
Hormones
Drug Therapy

Keywords

  • Chemotherapy
  • Radiation therapy
  • Radical prostatectomy

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Preliminary assessment of magnetic resonance spectroscopic imaging in predicting treatment outcome in patients with prostate cancer at high risk for relapse. / Pucar, Darko; Koutcher, Jason A.; Shah, Ankoor; Dyke, John P.; Schwartz, Lawrence; Thaler, Howard; Kurhanewicz, John; Scardino, Peter T.; Kelly, W. Kevin; Hricak, Hedvig; Zakian, Kristen L.

In: Clinical Prostate Cancer, Vol. 3, No. 3, 01.01.2004, p. 174-181.

Research output: Contribution to journalArticle

Pucar, D, Koutcher, JA, Shah, A, Dyke, JP, Schwartz, L, Thaler, H, Kurhanewicz, J, Scardino, PT, Kelly, WK, Hricak, H & Zakian, KL 2004, 'Preliminary assessment of magnetic resonance spectroscopic imaging in predicting treatment outcome in patients with prostate cancer at high risk for relapse', Clinical Prostate Cancer, vol. 3, no. 3, pp. 174-181. https://doi.org/10.3816/CGC.2004.n.028
Pucar, Darko ; Koutcher, Jason A. ; Shah, Ankoor ; Dyke, John P. ; Schwartz, Lawrence ; Thaler, Howard ; Kurhanewicz, John ; Scardino, Peter T. ; Kelly, W. Kevin ; Hricak, Hedvig ; Zakian, Kristen L. / Preliminary assessment of magnetic resonance spectroscopic imaging in predicting treatment outcome in patients with prostate cancer at high risk for relapse. In: Clinical Prostate Cancer. 2004 ; Vol. 3, No. 3. pp. 174-181.
@article{4b35ed9c26914e02b7b94ae3ebd9d87f,
title = "Preliminary assessment of magnetic resonance spectroscopic imaging in predicting treatment outcome in patients with prostate cancer at high risk for relapse",
abstract = "The purpose of the study was to determine whether 3D proton magnetic resonance spectroscopic imaging (MRSI) can predict treatment outcome in high risk patients with prostate cancer, Endorectal magnetic resonance imaging (MRI) and 1H-MRSI were performed in 16 patients with prostate cancer who were considered high risk because of clinical stage T3-4, Gleason score ≥ 8, and/or prostate-specific antigen (PSA) level > 20 ng/mL. Patients were treated with chemotherapy/hormone therapy, underwent radical prostatectomy (RP) or radiation therapy, and were followed for PSA relapse (follow-up, 19-43 months). The ratio of choline plus creatine to citrate was used to localize peripheral zone cancer. An MRSI risk score on a scale of 0-3 was derived from the volume and degree of metabolic abnormality. Magnetic resonance spectroscopic imaging risk score, MRI tumor/node (TN) stage, clinical stage, Gleason score, and PSA were used as predictors of pathologic stage in patients treated with RP (n = 10) and PSA relapse in all patients. Magnetic resonance imaging TN stage (P < 0.01) and MRSI risk score (P < 0.05) correlated with pathologic stage, but clinical stage did not (P = 0.35). Magnetic resonance imaging TN stage was the only significant predictor of PSA relapse in the univariate analysis (P < 0.05). Although the MRSI risk score did not reach significance (P = 0.13), 6 patients with a score < 0.9 were relapse-free, whereas 7 of 10 patients with a score > 0.9 relapsed. Magnetic resonance imaging and MRSI risk assessments agreed in 15 of 16 patients. These preliminary results suggest that tumor metabolic assessment may indicate treatment outcome in high-risk patients with prostate cancer. Although MRSI did not provide added prognostic value to MRI in this small number of patients, MRSI might increase the confidence of the clinician in assessing risk on MRI by contributing supporting metabolic data.",
keywords = "Chemotherapy, Radiation therapy, Radical prostatectomy",
author = "Darko Pucar and Koutcher, {Jason A.} and Ankoor Shah and Dyke, {John P.} and Lawrence Schwartz and Howard Thaler and John Kurhanewicz and Scardino, {Peter T.} and Kelly, {W. Kevin} and Hedvig Hricak and Zakian, {Kristen L.}",
year = "2004",
month = "1",
day = "1",
doi = "10.3816/CGC.2004.n.028",
language = "English (US)",
volume = "3",
pages = "174--181",
journal = "Clinical Genitourinary Cancer",
issn = "1558-7673",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Preliminary assessment of magnetic resonance spectroscopic imaging in predicting treatment outcome in patients with prostate cancer at high risk for relapse

AU - Pucar, Darko

AU - Koutcher, Jason A.

AU - Shah, Ankoor

AU - Dyke, John P.

AU - Schwartz, Lawrence

AU - Thaler, Howard

AU - Kurhanewicz, John

AU - Scardino, Peter T.

AU - Kelly, W. Kevin

AU - Hricak, Hedvig

AU - Zakian, Kristen L.

PY - 2004/1/1

Y1 - 2004/1/1

N2 - The purpose of the study was to determine whether 3D proton magnetic resonance spectroscopic imaging (MRSI) can predict treatment outcome in high risk patients with prostate cancer, Endorectal magnetic resonance imaging (MRI) and 1H-MRSI were performed in 16 patients with prostate cancer who were considered high risk because of clinical stage T3-4, Gleason score ≥ 8, and/or prostate-specific antigen (PSA) level > 20 ng/mL. Patients were treated with chemotherapy/hormone therapy, underwent radical prostatectomy (RP) or radiation therapy, and were followed for PSA relapse (follow-up, 19-43 months). The ratio of choline plus creatine to citrate was used to localize peripheral zone cancer. An MRSI risk score on a scale of 0-3 was derived from the volume and degree of metabolic abnormality. Magnetic resonance spectroscopic imaging risk score, MRI tumor/node (TN) stage, clinical stage, Gleason score, and PSA were used as predictors of pathologic stage in patients treated with RP (n = 10) and PSA relapse in all patients. Magnetic resonance imaging TN stage (P < 0.01) and MRSI risk score (P < 0.05) correlated with pathologic stage, but clinical stage did not (P = 0.35). Magnetic resonance imaging TN stage was the only significant predictor of PSA relapse in the univariate analysis (P < 0.05). Although the MRSI risk score did not reach significance (P = 0.13), 6 patients with a score < 0.9 were relapse-free, whereas 7 of 10 patients with a score > 0.9 relapsed. Magnetic resonance imaging and MRSI risk assessments agreed in 15 of 16 patients. These preliminary results suggest that tumor metabolic assessment may indicate treatment outcome in high-risk patients with prostate cancer. Although MRSI did not provide added prognostic value to MRI in this small number of patients, MRSI might increase the confidence of the clinician in assessing risk on MRI by contributing supporting metabolic data.

AB - The purpose of the study was to determine whether 3D proton magnetic resonance spectroscopic imaging (MRSI) can predict treatment outcome in high risk patients with prostate cancer, Endorectal magnetic resonance imaging (MRI) and 1H-MRSI were performed in 16 patients with prostate cancer who were considered high risk because of clinical stage T3-4, Gleason score ≥ 8, and/or prostate-specific antigen (PSA) level > 20 ng/mL. Patients were treated with chemotherapy/hormone therapy, underwent radical prostatectomy (RP) or radiation therapy, and were followed for PSA relapse (follow-up, 19-43 months). The ratio of choline plus creatine to citrate was used to localize peripheral zone cancer. An MRSI risk score on a scale of 0-3 was derived from the volume and degree of metabolic abnormality. Magnetic resonance spectroscopic imaging risk score, MRI tumor/node (TN) stage, clinical stage, Gleason score, and PSA were used as predictors of pathologic stage in patients treated with RP (n = 10) and PSA relapse in all patients. Magnetic resonance imaging TN stage (P < 0.01) and MRSI risk score (P < 0.05) correlated with pathologic stage, but clinical stage did not (P = 0.35). Magnetic resonance imaging TN stage was the only significant predictor of PSA relapse in the univariate analysis (P < 0.05). Although the MRSI risk score did not reach significance (P = 0.13), 6 patients with a score < 0.9 were relapse-free, whereas 7 of 10 patients with a score > 0.9 relapsed. Magnetic resonance imaging and MRSI risk assessments agreed in 15 of 16 patients. These preliminary results suggest that tumor metabolic assessment may indicate treatment outcome in high-risk patients with prostate cancer. Although MRSI did not provide added prognostic value to MRI in this small number of patients, MRSI might increase the confidence of the clinician in assessing risk on MRI by contributing supporting metabolic data.

KW - Chemotherapy

KW - Radiation therapy

KW - Radical prostatectomy

UR - http://www.scopus.com/inward/record.url?scp=19944418214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944418214&partnerID=8YFLogxK

U2 - 10.3816/CGC.2004.n.028

DO - 10.3816/CGC.2004.n.028

M3 - Article

C2 - 15636684

AN - SCOPUS:19944418214

VL - 3

SP - 174

EP - 181

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

SN - 1558-7673

IS - 3

ER -